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Abstract
Introduction: Visceral adiposity is associated with decreased serum adiponectin levels, peripheral resistance to insulin, and an increased 
risk of cardio-metabolic complications. However, the link between adiponectin expression in visceral adipose tissue (VAT), its serum 
levels, and metabolic protection is controversial. The aim of this study was to investigate the relationship between the adiponectin gene 
expression in VAT and clinical and metabolic parameters in patients with severe obesity.
Material and methods: This is a cross-sectional study that included 51 severely obese patients (age 43.24 ± 11.29 years, BMI 45.13 ± 
8.67 kg/m2), extensively evaluated clinically and biologically (metabolic tests, serum adiponectin measurements, HOMA-IR) before bariatric 
surgery. Omental adipose tissue was sampled during the intervention and the relative quantification of adiponectin gene expression was 
performed by real-time PCR.
Results: Adiponectin mRNA in VAT was significantly higher in obese insulin-sensitive patients than in the rest of the obese patients 
(p < 0.05) and negatively correlated with HOMA-IR (r = –0.354, p = 0.016) and uric acid (r = –0.304, p = 0.045). After adjustment for 
gender, TG/HDL ratio and uric acid, adiponectin expression (b = –0.439, p = 0.001), waist circumference (b = 0.467, p = 0.001), and serum 
adiponectin (b = –0.339, p = 0.011) remained significantly associated with HOMA-IR, together explaining more than 50% of its variation.
Conclusions: In severely obese patients, adiponectin gene expression in VAT is negatively correlated with serum levels of uric acid and 
is an independent determinant, together with anthropometric parameters of visceral obesity and serum adiponectin levels, of insulin 
resistance. (Endokrynol Pol 2018; 69 (3): 252–258)
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Streszczenie
Wstęp: Otyłość trzewna związana jest ze zmniejszonym stężeniem adiponektyny w surowicy krwi, obwodową opornością na działanie 
insuliny oraz ze zwiększonym ryzykiem powikłań sercowo-metabolicznych. Jednak związek między ekspresją adiponektyny w trzewnej 
tkance tłuszczowej, jej stężeniem w surowicy krwi a ochroną metaboliczną jest kwestią sporną. Celem niniejszej pracy było zbadanie 
związku między ekspresją genu adiponektyny w trzewnej tkance tłuszczowej a klinicznymi i metabolicznymi parametrami pacjentów 
ze znaczną otyłością.
Materiał i metody: To przekrojowe badanie obejmowało 51 znacznie otyłych pacjentów (wiek 43,24 ± 11,29 roku, BMI 45,13 ± 8,67 kg/m2), 
szczegółowo ocenionych pod względem klinicznym i biologicznym (testy metaboliczne, pomiary stężenia adiponektyny w surowicy 
krwi, wskaźnik HOMA-IR) przed operacją bariatryczną. Podczas operacji pobrano tkankę tłuszczową sieci. Względna ocena ilościowa 
ekspresji genu adiponektyny była przeprowadzona metodą PCR w czasie rzeczywistym.
Wyniki: Poziom mRNA adiponektyny w trzewnej tkance tłuszczowej był znacząco wyższy u otyłych pacjentów wrażliwych na insulinę 
niż u pozostałych otyłych pacjentów (p < 0,05) oraz ujemnie skorelowany ze wskaźnikiem HOMA-IR (r = –0,354, p = 0,016) i kwasem 
moczowym (r = –0,304, p=0.045). Po uwzględnieniu płci, wskaźnika TG/HDL i kwasu moczowego, ekspresja adiponektyny (b = –0,439, 
p = 0,001), obwód talii (b = 0,467, p = 0,001) i poziom adiponektyny w surowicy krwi (b = –0,339, p = 0,011) pozostały istotnie związane 
ze wskaźnikiem HOMA-IR, łącznie wyjaśniając ponad 50% jego wariancji.
Wnioski: W przypadku znacznie otyłych pacjentów ekspresja genu adiponektyny w trzewnej tkance tłuszczowej jest ujemnie skorelo-
wana ze stężeniem kwasu moczowego w surowicy krwi i razem z antropometrycznymi parametrami otyłości trzewnej oraz stężeniem 
adiponektyny w surowicy krwi jest niezależnym wyznacznikiem insulinooporności. (Endokrynol Pol 2018; 69 (3): 252–258)
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Introduction
Obesity has been associated with a substantial am-
plification in the risk of cardiovascular and metabolic 
diseases, with increased morbidity and mortality [1, 2]. 
However, these conditions do not occur invariably in 
obese patients, with some groups of individuals being 
more susceptible or, on the contrary, somehow pro-
tected against developing cardio-metabolic pathology.
Numerous studies have shown abdominal adiposity 
to be strongly correlated with insulin resistance, with 
differences in the amount of visceral fat explaining 
routinely the variability of insulin sensitivity in obese 
patients [3]. These clinical observations led to the so-
called “portal paradigm” that hypertrophied visceral 
adipocytes, whose basal lipolysis is enhanced in obe-
sity, release increased levels of free fatty acids into the 
portal system, which leads to hepatic insulin resistance 
and failure of pancreatic beta-cells [4]. This theory has 
been questioned in recent years by the discovery of the 
endocrine role of adipose tissue and of the pleiotropic 
adipocytokines, involved in the control of many meta-
bolic processes.
Adiponectin, the adipocyte hormone with the high-
est plasma concentration, is considered a modulator 
of carbohydrate and lipid metabolism and a marker 
of insulin sensitivity [5]. Although mainly produced 
in adipose tissue, serum adiponectin concentrations 
are negatively correlated with the amount of visceral 
adiposity [6]. However, the link between adiponectin 
expression in adipose tissue, its serum levels, and meta-
bolic protection is controversial.
The aim of our study was to investigate the rela-
tionship between the adiponectin gene expression 
in visceral adipose tissue and clinical and metabolic 
parameters in patients with severe obesity, undergoing 
bariatric surgery. 
Material and methods
The study group included 51 patients (70.5% women, 
29.5% men) with severe obesity, who underwent lapa-
roscopic sleeve gastrectomy in a highly specialised Bari-
atric Surgery Clinic. All patients met the 1991 NIH Con-
sensus Conference guidelines for bariatric surgery [7]. 
This study was conducted according to the standards 
of good clinical practice and the Declaration of Helsinki 
and was approved by the institutional Ethics Com-
mittee (Decision 1/10.02.2011). All patients signed an 
informed consent form.
Approximately one month before surgery, patients 
were extensively evaluated in our Endocrinology, 
Diabetes, and Nutrition Disorders Department, as de-
scribed elsewhere [8]. Exclusion criteria were: diabetic 
patients requiring insulin due to difficulties in assess-
ing insulin resistance, as well as patients with severe 
chronic kidney disease (estimated glomerular filtration 
rate < 30 mL/min), liver failure, cancer, and other severe 
systemic diseases.
Body weight was measured in light clothing and 
without shoes, to the nearest 0.5 kg; height was meas-
ured to the nearest 0.5 cm; waist circumference (WC) 
was measured at the midway between the lower border 
of the rib cage and the iliac crest, while hip circumfer-
ence was measured around the widest portion of the 
buttocks. After overnight fasting, blood samples were 
obtained and immediately used for the determination of 
glucose, liver enzymes, uric acid, total cholesterol, high-
density lipoprotein (HDL) cholesterol, low-density li-
poprotein (LDL) cholesterol, and triglycerides (TG). For 
the other tests, plasma was separated by centrifugation 
at 4000 rpm/min for 6 minutes at 20° C and then frozen 
at –80°C. Insulin and high-sensitivity C-reactive protein 
(hs-CRP) were assayed using a two-site, solid-phase, 
enzyme-labelled chemiluminescent immunometric 
assay (Immulite 2000, Siemens Healthcare Diagnostics 
Products Ltd.). Serum adiponectin and TNF-a levels 
were measured using an ELISA kit (DRG Instruments, 
Germany). For adiponectin the detection rate was 
0.39 mg/l, the intra-assay CV was 0.9–7.4%, and the 
inter-assay CV was 2.4–8.4%. For TNF-a the detection 
rate was 0.7 pg/ml, the intra-assay CV was 6.3–6.6%, 
and the inter-assay CV was 3.3–4.5%.
In all patients not previously diagnosed with 
diabetes mellitus, we performed a 75-g oral glucose 
tolerance test (OGTT), with blood samples taken at 
0 and 2 hours. In conformity with the American Dia-
betes Association criteria [9] all patients with fasting 
plasma glucose ≥ 126 mg/dL or 2-hour plasma glucose 
≥ 200 mg/dL during OGTT were considered as having 
diabetes mellitus. Patients with fasting plasma glucose 
between 100 and 125 mg/dL or with two-hour plasma 
glucose between 140 and 200 mg/dL were considered 
as having prediabetes [9].
To assess IR, the homeostasis model assessment of 
IR (HOMA-IR) was used [10]. Non-diabetic patients in 
the inferior quartile of HOMA (that is HOMA < 2.85) 
were considered insulin sensitive (IS+), while the rest 
of the patients were considered insulin resistant (IS–). 
Visceral adiposity index (VAI), a novel sex-specific in-
dex highly correlated with visceral adiposity measured 
by magnetic resonance imaging (the gold standard 
method), was defined using the Amato formula [11]:
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Patients were considered to have metabolic syn-
drome according to the National Cholesterol Education 
Program Adult Treatment Panel III definition [8].
Biological material
A piece of omental adipose tissue of about 0.5 g was 
sampled from all patients during surgery and was 
immediately submerged in RNA preserving solution 
(RNAlater — Qiagen GmbH Germany) and stored at 
–80° C, for further analysis of adiponectin gene expres-
sion (mRNA). The relative quantification of adiponectin 
gene expression was performed by real-time PCR, using 
beta-actin as a reference gene.
Isolation of total RNA
Total RNA was extracted from visceral fat sample with 
TRI Reagent (Sigma-Aldrich). The concentration and 
purity of extracted RNA was quantified using a spectro-
photometer Biospec-Nano (Shimadzu Biotech, Kyoto, 
Japan), and the RNA integrity was checked by visual 
inspection of the bands corresponding to the 28S rRNA 
and 18S rRNA by electrophoresis in 2% agarose gel.
Adiponectin gene expression was assessed by real-
time RT-PCR. For reverse transcription reaction total 
RNA was used together with the iScript synthesis kit 
(Bio-Rad, Hercules, CA, USA) and the protocol indi-
cated by the manufacturer.
The set of primers used in the amplification reac-
tion were selected using Primer 3 program, namely: 
Adiponectin: forward primer 5’-CATGACCAGGAAAC-
CACGACT-3’ and reverse primer 5’-TGAATGCTGAGC-
GGTAT-3’; reference gene, b actin: forward primer 
5’-GCCTCGCTGTCCACCTTCC-3’ and reverse primer 
5’-GCTGTCACCTTCACCGTTCC -3’.
The reactions were performed on a thermocycler 
iCycler iQ (Bio-Rad) using an excitation filter set/ 
/transmitter specific for the SYBR Green (lex 490 nm/ 
/lem 530 nm). Quantitative PCR reaction was per-
formed in a final volume of 25 μL containing 5 μL of 
diluted template cDNA, 12.5 μL 2 × BioRad iQ SYBR 
Green Supermix™, 200 nM of each sense and antisense 
primer. The amplification program consisted of: initial 
denaturation cycle — 95°C, 3 min 30 sec.; 45 cycles of 
amplification: denaturation — 30 sec. 95°C, hybridisa-
tion — 30 sec. 58°C, elongation and fluorescent signal 
acquisition — 30 sec. 72°C; the program for determining 
the melting curve: 85 cycles of 10 seconds each, with an 
increasing variation of temperature in 0.5°C increments, 
starting at 55°C.
Changes in the level of adiponectin to beta-actin 
mRNA were calculated based on the formula [12] 
(1/2)CT adiponectin−CT b-actin. All determinations were made 
in triplicate and the arithmetic mean of the results was 
used for the analysis.
Statistical processing
Statistical analysis was performed using SPSS software 
(SPSS Inc., Chicago IL), version 17.0. Continuous vari-
ables with normal distribution are presented as mean ± 
standard deviation (SD), and those with non-Gaussian 
distribution are presented as medians (interquartile 
range). The value of adiponectin expression (corrected 
to beta-actin) was used as a decimal logarithm. Compar-
isons between groups were made using parametric and 
non-parametric tests (Student t-test or Mann-Whitney 
test for continuous variables, the chi-square test for cat-
egorical ones). Correlations were performed using the 
Pearson/Spearman test, and linear regression analysis 
was used to identify the influence of various parameters 
on the level of HOMA-IR. P < 0.05 was considered as 
statistically significant for all tests.
Results
Our study included 51 severely obese patients (36 wom-
en), with mean BMI = 45.13 ± 8.67 kg/m2 (men: 49.99 
± 10.64 kg/m2, women: 43.11 ± 6.92 kg/m2, p = 0.008) 
and mean age = 43.24 ± 11.29 years (no significant dif-
ference between genders). Eleven patients (21.5%) had 
type 2 diabetes and another 11 had prediabetes (two 
with impaired fasting glucose and 11 with impaired 
glucose tolerance).
Table I presents the general characteristics of the 
study patients, according to the presence of insulin 
sensitivity. Since no statistically significant differences 
were observed between adiponectin gene expression 
in omental fat in men and women, all patients were 
included in the analysis, without gender segregation. 
As expected, the insulin-sensitive obese group had 
a lower WHR (although there was no significant dif-
ference in BMI level or in gender-adjusted weight) 
and a significantly more beneficial metabolic profile 
(higher values of HDL-cholesterol, and lower levels 
of triglycerides, uric acid, and visceral adiposity index 
— VAI). The presence of insulin sensitivity was also 
associated with lower levels of inflammation markers 
(C-reactive protein, TNF-alpha) and higher values of 
serum adiponectin.
Adiponectin gene expression in visceral adipose tis-
sue was significantly higher in obese insulin-sensitive 
patients than in the rest of the obese patients (Table I). 
This difference is maintained and becomes even more 
evident after adjustment for gender and BMI (Figure 1).
In univariate analysis, there was no significant cor-
relation between adiponectin gene expression in the vis-
ceral adipose tissue and anthropometric indices (such 
as weight, BMI, waist circumference, or WHR) or with 
serum adiponectin level. Among metabolic parameters, 
adiponectin expression was negatively correlated with 
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HOMA-IR (r = –0.354, p = 0.016) and uric acid, after 
gender adjustment (r = –0.304, p = 0.045).
In the following stage of the analysis we tried to 
identify the role of adiponectin gene expression as 
a determinant of insulin resistance assessed by HOMA-
IR. Other clinical and biological parameters significantly 
correlated with HOMA-IR in the univariate analysis 
were: waist circumference (r = 0.343, p = 0.017), 
HDL-cholesterol (r = –0.388, p = 0.009), triglycerides 
(r = 0.355, p = 0.013), TG/HDL ratio (r = 0.450, p = 0.002), 
uric acid (r = 0.431, p = 0.003), and serum adiponectin 
(r = –0.314, p = 0.036). Gender was another significant 
determinant of HOMA-IR levels (HOMA-IR — logarith-
mic value — for women: 0.516 ± 0.25, for men: 0.688 ± 
0.27, p = 0.047)
A linear regression analysis, stepwise method 
was subsequently performed, with HOMA-IR as the 
dependent variable and factors previously shown to 
significantly correlate to its level as independent vari-
ables (gender, waist circumference, TG/HDL ratio, uric 
acid, serum adiponectin, adiponectin gene expression). 
In this model, serum adiponectin, waist circumference, 
Table I. General characteristics of the patients included in the study according to insulin sensitivity
Tabela II. Ogólna charakterystyka pacjentów objętych badaniem w zależności od wrażliwości na insulinę
IS+ (n = 15) IS– (n = 36) p
Gender — female (%) 93.3% 61.1% 0.04
Age (years) 41.33 ± 12.99 44.03 ± 10.6 NS
Smokers (%) 40% 38.9% NS
Weight [kg] 112.07 ± 13.24 130.42 ± 29,86 0.027
BMI [kg/m2] 42.37 ± 7.02 46.28 ± 9.11 NS
WC [cm] 114.67 ± 18.15 129 ± 20.15 0.021
WHR 0.86 ± 0.08 0.95 ± 0.1 0.005
*HDL-cholesterol [mg/dl] 56 (27) 43 (13) 0.02
Triglycerides [mg/dl] 115.27 ± 45.52 172.61 ± 55.67 0.001
*LDL-cholesterol [mg/dl] 115 (50) 130 (43) NS
Total cholesterol [mg/dl] 206.53 ± 40.56 205.86 ± 31.03 NS
*VAI 4.1 (2.66) 6.38 (5.23) 0.001
Hypertensive (%) 40% 52% NS
MetS (%) 40% 77.8% 0.02
Uric acid [mg/dl] 5.02 ± 1.17 6.06 ± 1.35 0.019
*CRP [mg/dl] 0.39 (0.76) 0.73 (1.28) 0.028
*TNF-alpha [pg/ml] 5.2 (1.5) 6.6 (2.2) 0.016
*Plasma adiponectin [mg/l] 7.72 (1.26) 6.49 (2.65) 0.019
Adiponectin gene relative expression –1.89 ± 0.6 –2.23 ± 0.57 0.038
*marks variables with non-Gaussian distribution
Continuous variables with normal distribution are presented as mean ± standard deviation (SD), while those with non-Gaussian distribution are presented as medians 
(interquartile range).
IS+ — insulin sensitive patients; IS- — patients without insulin sensitivity; BMI — body mass index; WC — waist circumference; WHR — waist/hip ratio;  
VAI — visceral adiposity index; MetS — metabolic syndrome; CRP — C reactive protein; TNF — tumoural necrosis factor
and adiponectin gene expression in visceral adipose 
tissue were independent determinants of HOMA-IR 
levels, together explaining about 50% of its variability 
(Table II).
Discussion
This study analyses the link between adiponectin gene 
expression in visceral adipose tissue (VAT) and biologi-
cal and clinical parameters in severely obese patients. 
Our data showed no relationship between adiponectin 
mRNA from VAT and anthropometric indices (BMI, 
waist circumference) or serum levels of adiponectin, 
but a negative correlation with two of the parameters 
of metabolic damage in obesity — uric acid levels and 
HOMA-IR. In regression analysis, adiponectin gene 
expression level was an independent determinant of 
HOMA-IR value, and, together with serum concentra-
tion of adiponectin and waist circumference, explained 
more than 50% of its variability. 
It is well-known that obese patients have low levels 
of serum adiponectin [13], while low plasma adiponec-
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tin concentrations predict increases in visceral adipos-
ity and insulin resistance, but the mechanisms behind 
this association have not been fully elucidated [14]. 
One hypothesis stipulates a defect in adiponectin 
synthesis at adipocyte level, because circulating levels 
of adiponectin are directly related to production of 
adipocytes due to adiponectin being secreted almost 
exclusively by mature adipocytes [15]. There have been 
several studies investigating the relationship between 
adiponectin gene expression in various adipose tissue 
compartments and patients’ anthropometric para-
meters, but the results are contradictory. While negative 
correlation between adiponectin gene expression in 
the subcutaneous adipose tissue and BMI was certified 
by several authors [16], the link between adiponectin 
mRNA in visceral adipocytes and overall adiposity is 
less obvious, with some studies that support a link [16] 
and other that do not identify a relationship with BMI 
[17, 18]. In the present study we could not establish 
a clear correlation between adiponectin gene expression 
in omental adiposity and BMI or other anthropometric 
parameters. A possible explanation is the profile of our 
group of patients: relatively young and with severe 
obesity but without an extremely deteriorated meta-
bolic pattern. In these patients, the characteristically 
increased subcutaneous fat deposits may even have 
a protective role, leading to a prevalence of metabolic 
disorders significantly lower than expected compared 
to overweight or normal-weight patients [19].
Our study could not reveal a relationship between 
adiponectin mRNA in visceral adipose tissue and its 
serum levels. This might be due to the differences in 
morphology and cellularity among the adipose tissue 
depots or to the differential impact of various adiposity 
compartments on adiponectin serum concentration. In 
vitro studies have shown that adiponectin gene expres-
sion is more reduced in visceral fat than in subcutane-
ous compartment, which suggests that the latter may 
be more important for the circulating adiponectin. In 
addition, in a population-based study including nearly 
800 young Danes, Frederiksen concluded that subcu-
taneous adiposity, rather than the visceral, is a major 
determinant of serum adiponectin levels [20]. Other 
possible explanations for the lack of a relationship be-
tween adiponectin mRNA and its serum level may be 
the existence of a posttranscriptional defect in protein 
translation or secretion, or its enhanced capture/degra-
dation in obese patients. Studies in patients receiving 
PPAR-g agonists showed a significant increase in total 
adiponectin levels, unaccompanied by change of adi-
ponectin mRNA, suggesting that regulation is made at 
posttranscriptional level [21]. In another study evaluat-
ing the effect of pioglitazone on adiponectin translation, 
Banga et al. identified an adipocitary cytoplasm factor, 
most probably a protein, that constitutively inhibits adi-
ponectin translation in obese patients, as an important 
component of insulin resistance syndrome [22].
Even in the absence of a clear relationship with BMI, 
adiponectin gene mRNA in VAT was negatively corre-
lated with two of the biological parameters which char-
acterise metabolic damage in obesity — uric acid serum 
Figure 1. Adiponectin gene relative expression in visceral adipose 
tissue, according to insulin sensitivity status. Bars illustrate 
estimated marginal means ± SE of adiponectin expression, as 
determined by analysis of covariance after adjustment for gender 
and BMI
Rycina 1. Względna ekspresja genu adiponektyny w trzewnej 
tkance tłuszczowej, zgodnie ze stanem wrażliwości na insulinę. 
Słupki na wykresie ilustrują przybliżone wartości brzegowe ± 
SE (standard error; błąd standardowy) ekspresji adiponektyny, 
określone przez analizę kowariancji po uwzględnieniu płci 
i wskaźnika BMI
Table II. Multiple regression analysis, stepwise method, the 
determinants of HOMA-IR
Tabela II. Analiza regresji wielokrotnej, metoda krokowa, 
determinanty HOMA-IR
Dependent 
variable
Independent  
variable
B P
*HOMA-IR 
(r2 = 0.503,  
p < 0.001) *Serum adiponectin –0.339 0.011
Waist circumference 0.467 0.001
*Adiponectin gene 
expression
–0.439 0.001
*marks logarithmically transformed variables
Excluded variables: gender, TG/HDL ratio, uric acid
257
Endokrynologia Polska 2018; 69 (3)
PR
A
C
E 
O
RY
G
IN
A
LN
E
levels and insulin resistance, estimated by HOMA-IR. 
Regarding uric acid, there are several studies proving 
that hyperuricaemia is not only a secondary marker of 
obesity and its associated insulin resistance, but also 
a potential determinant of metabolic syndrome [23]. In 
a research project that investigated the effect of hyperu-
ricaemia on the production of adiponectin, Baldwin 
showed that uric acid causes a dramatic reduction of 
adiponectin mRNA in murine and human adipocyte 
cell lines, and its effect seems to be mediated by inhi-
bition of PPAR-g [24]. In our study we also identified 
a negative correlation between serum levels of uric acid 
and adiponectin gene expression in visceral adipose 
tissue, and, furthermore, this relationship proved to 
be independent of BMI, which demonstrates the role 
of uric acid as a marker (or maybe determinant) of 
metabolic complications in patients with severe obesity. 
One of the important results of this study was the 
demonstration of a negative correlation between omen-
tal expression of adiponectin gene and HOMA-IR. This 
relationship remained significant after adjustment for 
serum levels of adiponectin and waist circumference, 
and together these three parameters explained about 
50% of HOMA-IR variability. It is well known that in 
obese patients, the amount of intra-abdominal adipose 
tissue is one of the most important determinants of 
the degree of insulin resistance [25]. Compared with 
subcutaneous adipocytes, the visceral ones are less 
sensitive to insulin and have a higher level of basal 
lipolysis, which leads to the release of free fatty acids 
and pro-inflammatory adipokines (TNF-alpha, IL-6) in 
the portal system and subsequent insulin-resistance [4]. 
Our study showed that obese patients with insulin 
sensitivity have a higher level of adiponectin mRNA 
than the insulin resistant ones. Furthermore, in linear 
regression analysis, both adiponectin gene visceral 
expression and serum adiponectin were independent 
predictors of HOMA-IR. Similar results were recently 
reported by Chen et al., who analysed adiponectin gene 
expression in the omental adipose tissue in 40 patients, 
of whom 25 were obese and showed an inverse corre-
lation with HOMA-IR. In the same study, adiponectin 
gene expression was significantly increased (by about 
five times) after gastric bypass intervention, paralleling 
the improvement in insulin resistance [26].
We are aware that this study has some limitations 
that originate firstly from the relatively small number 
of analysed patients and, on the other hand, from the 
inability to properly quantify the distribution of adipo-
sity, which would have brought additional information 
on the contribution of visceral fat in the determinism 
of insulin resistance. It would have been also useful to 
determine adiponectin complexes of high molecular 
weight (HMW) because it is well-know that many of 
the beneficial effects of adiponectin are due to this iso-
form, especially those related to insulin sensitivity and 
protection against cardiovascular diseases [27].
Conclusions
In conclusion, we showed that, in severely obese pa-
tients, adiponectin gene expression in visceral adipose 
tissue is negatively correlated with serum levels of uric 
acid and is an independent determinant, together with 
anthropometric parameters of visceral obesity and se-
rum adiponectin levels, of insulin resistance.
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